Want to see AU:NOX full AI Analyst Report?
NOX Stock Chart & Stats
AU$0.10
>-AU$0.01(-7.87%)
At close: 4:00 PM EDT
AU$0.10
>-AU$0.01(-7.87%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.11
Previous CloseN/A
Volume10.31K
Average Volume (3M)82.76K
Market Cap
AU$19.97M
Enterprise ValueAU$29.70
Total Cash (Recent Filing)AU$293.57K
Total Debt (Recent Filing)AU$4.57M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding307,237,950
10 Day Avg. Volume87,995
30 Day Avg. Volume82,760
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)-7.08
Price to Sales (P/S)18.11
P/FCF Ratio-9.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oncology R&D FocusA focused oncology pipeline gives Noxopharm a clear strategic direction in a large, medically important market. Candidates designed to enhance radiotherapy and other anti-cancer modalities could provide differentiated treatment value if development succeeds, supporting longer-term commercial potential.
Narrower Operating LossThe reduction in operating losses indicates improved cost control or lower expense intensity, which is constructive for financial discipline. Although profitability remains distant, sustained progress could extend the company’s development runway and reduce the scale of future funding needs.
Improved Cash BurnA materially smaller cash outflow improves near-term resource efficiency for an R&D-heavy biotech company. If maintained, this trend could preserve funding for priority oncology programs, slow balance-sheet deterioration, and provide more time to achieve clinical or commercial milestones.
Bears Say
Persistent UnprofitabilityOngoing operating and net losses show that the business has not yet established a profitable operating model. Continued unprofitability limits internally generated funding, increases reliance on capital markets, and leaves future earnings dependent on successful development and commercialization.
Negative Equity And Higher DebtNegative equity combined with rising debt signals significant accumulated losses and reduced financial flexibility. This structure can constrain investment in the pipeline, increase dependence on external capital, and make the company more vulnerable if additional funding becomes difficult to secure.
Revenue ContractionA sharp recent revenue contraction weakens the foundation for scaling the business and makes fixed development costs harder to absorb. Without a sustained revenue recovery, Noxopharm may remain far from break-even and continue depending on financing to support its R&D activities.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.05 and its highest was AU$0.11 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$19.97M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Mar 02, 2027 which is in 165 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.009 earnings per share for the quarter.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 307,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NOX Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―